Fw: Bendamustine plus rituximab offers practice-changing therapy for indolent lymphoma

[Guest guest]

American Society of Hematology Annual Exposition 2009

Bendamustine plus rituximab offers practice-changing therapy for

indolent lymphoma

To view this email as a web page, click here.

Publications News Conference Reports Podcasts CME

E-Learning Classifieds Supplements Practice Management For Patients

Four-drug regimen ups response, progression-free

survival in older multiple myeloma patients

More is better, at least when it comes to treatments for

multiple myeloma. Separate studies from a Spanish group and an Italian group

showed that up-front use of four drugs improves durable responses and

progression-free survival in elderly patients. Both studies also showed that a

kinder, gentler weekly schedule of bortezomib (Velcade) instead of the standard

twice-weekly schedule maintains efficacy and reduces toxicity.

Oral JAK2 inhibitor deflates symptoms in myelofibrosis

disease

A new treatment for patients who are severely

debilitated by myelofibrosis offers hope of a return to normal daily life.

Preliminary studies with an oral drug INCB018424 that targets the

Janus-activated kinase (JAK) 2 gene appears to markedly reduce the swelling of

the spleen and sometimes the liver, which can, in turn, can change patients'

quality of life.

Bendamustine plus rituximab offers practice-changing

therapy for indolent lymphoma

There was good news at ASH 2009 on promising treatments

for indolent lymphoma and aggressive non-Hodgkin's lymphoma. Also, a separate

poster presentation showed that even just one cycle of post-remission therapy

extended survival in elderly patients with acute myeloid leukemia.

This email was sent by: CMPMedica

535 Connecticut Avenue, Suite 300 Norwalk, CT, 06854, USA

Update Profile